Category Archives: Psoriasis

"Psoriatic arthritis is a debilitating disease that can cause severe pain, restricted mobility, and lasting structural damage.4, 5The immune system creates inflammation that can lead to skin lesions associated with psoriasis, as well as pain, fatigue and stiffness in the joints," 6,7said Dr. Proton Rahman, FRCPC, Clinical Rheumatologist at Eastern Health and University Research Professor at Memorial University. "Despite treatment advances, somepeople living with PsA do not achieve their treatment goals, which is why access to new therapies is so critical. The approval of RINVOQ offers Canadian physicians and their patients an important new therapeutic option."

"I have had psoriatic arthritis and psoriasis for more than 30 years. At one point, most ofmy body was covered in psoriasis, and I was using arm and leg braces to help me walk. These diseases have had a huge impact on my life, which is why I am so pleased that Canadians with psoriatic arthritis now have a new treatment option available to them," said Marilyn Porth, of Winnipeg, Manitoba.

This approval is supported by data from two Phase 3 studies across a broad range of more than 2,000 patients with active psoriatic arthritis.1,2 In both studies, RINVOQ met the primary endpoint of ACR20 response at week 12 versus placebo.1,2 RINVOQ 15 mg also achieved non-inferiority versus adalimumab in terms of ACR20 response at week 12.1 Patients receiving RINVOQ also experienced greater improvements in physical function (HAQ-DI*) and skin symptoms (PASI 75*), and a greater proportion achieved minimal disease activity.1,2Overall, the safety profile of RINVOQ in psoriatic arthritis was consistent with previously reported results across the Phase 3 rheumatoid arthritis clinical trial program, with no new significant safety risks detected.1,2,8

"The approval of RINVOQ is wonderful news for Canadians living with psoriatic arthritis, and an important step forward for the psoriatic arthritis community," says Wendy Gerhart, Executive Director, Canadian Spondylitis Association. "From our recent member surveys, we know this devastating disease has a profound impact on people's quality of life including their physical and mental health. This approval provides a new treatment option to Canadian patients. It is a hopeful time for people living with psoriatic arthritis."

"For more than 20 years, AbbVie has been dedicated to discovering and delivering innovative therapies for people living with rheumatic diseases," added Tracey Ramsay, Vice President and General Manager, AbbVie Canada. "We are proud of our deep heritage in rheumatology and pleased to expand our portfolio of treatment options for Canadians living with psoriatic arthritis, particularly by offering people the convenience of a once-daily oral medication."

*Physical function was measured by the Health Assessment Questionnaire Disability Index (HAQ-DI). Skin symptoms were measured by a 75 percent improvement in the Psoriasis Area and Severity Index (PASI 75). Minimal disease activity is defined as the fulfillment of five of seven outcome measures: Tender joint count 1; swollen joint count 1; PASI 1 or body surface area-psoriasis 3 percent; Patient's Assessment of Pain Numerical Rating Scale (NRS) 1.5; Patient Global Assessment-Disease Activity NRS 2.0; HAQ-DI score 0.5; and Leeds Enthesitis Index 1.

About SELECT-PsA 1 1,3

SELECT-PsA 1is a Phase 3, multicenter, randomized, double-blind, parallel-group, active and placebo-controlled study designed to evaluate the safety and efficacy of upadacitinib compared to placebo and adalimumab in adult patients with active psoriatic arthritis who have a history of inadequate response to at least one non-biologic DMARD.

Top-line results from SELECT-PsA 1 were previously announced in February 2020. More information on this trial can be found atwww.clinicaltrials.gov(NCT03104400).

About SELECT-PsA 2 2,3

SELECT-PsA 2is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study designed to evaluate the safety and efficacy of RINVOQ in adult patients with active psoriatic arthritis who have a history of inadequate response to at least one biologic DMARD.

Top-line results from SELECT-PsA 2 were previously announced in October 2019. More information on this trial can be found atwww.clinicaltrials.gov(NCT03104374).

About RINVOQ(upadacitinib)

RINVOQ is a 15 mg, once-daily oral medication in an extended-release tablet. It is a Janus kinase (JAK) inhibitor that interferes with the JAK-STAT signaling pathway, which is thought to play a role in inflammatory response.

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate, as well as for adults with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other DMARDs. In RA, RINVOQ may be used as a monotherapy or in combination with methotrexate or other nonbiologic DMARDs. In PsA, RINVOQ may be used as a monotherapy or in combination with methotrexate.

For important safety information, please consult the RINVOQ Product Monograph at http://www.abbvie.ca.

About AbbVie in Rheumatology

For more than 20 years, AbbVie has been dedicated to improving care for people living with rheumatic diseases. Our longstanding commitment to discovering and delivering innovative therapies is underscored by our pursuit of cutting-edge science that improves our understanding of promising new pathways and targets in order to help more people living with rheumatic diseases reach their treatment goals.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at http://www.abbvie.ca. Follow @abbviecanadaon Twitter or find us on Facebook, Instagram, YouTubeand LinkedIn.

References

1.

McInnes I, et al. Efficacy and Safety of Upadacitinib Versus Placebo and Adalimumab in Patients With Active Psoriatic Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Anti-Rheumatic Drugs (SELECT-PsA-1): a Double-Blind, Randomized Controlled Phase 3 Trial. 2020 EULAR E-Congress; LB0001.

2.

Genovese MC, et al. Efficacy and Safety of Upadacitinib in Patients With Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs (SELECT-PsA-2): a Double-Blind, Randomized Controlled Phase 3 Trial. 2020 EULAR E-Congress; OP0223.

3.

RINVOQ (upadacitinib) product monograph. AbbVie Corporation. Available at: https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/RINVOQ_PM.pdf. Accessed June 7, 2021.

4.

Diseases & Conditions: Psoriatic Arthritis. 2019. American College of Rheumatology. Available at: https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Psoriatic-Arthritis. Accessed on: May 13, 2021.

5.

Schett G, et al. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res & Ther.2011; 13(Suppl1) :s4(1-9)

6.

uarte GV, et al. Psoriatic arthritis. Best Pract Res Clin Rheumatol. 2012 Feb;26(1):147-56. doi: 10.1016/j.berh.2012.01.003.

7.

Diseases & Conditions: Psoriatic Arthritis. 2019. American College of Rheumatology. Available at: https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Psoriatic-Arthritis. Accessed: December 2020

8.

Cohen S., et al. Safety profile of upadacitinib in Rheumatoid Arthritis: Integrated analysis from the SELECT Phase 3 Clinical Program. EULAR 2019; THU0167.

SOURCE AbbVie Canada

For further information: Media Inquiries: Julie Lepsetz, AbbVie Canada, (514) 451-9427, [emailprotected]

Continue reading here:
Health Canada Approves AbbVie's RINVOQ (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis - Canada NewsWire

The healthcare vertical is being driven at the consumers pace like never before. In other words, the requirements and goals on their part are driving innovation in every arm of the healthcare vertical. On-demand interactions between clinicians and patients all over the world are being asked for. As such, the healthcare vertical is bound to witness higher strides in the next 10 years.

The Systemic Psoriasis Therapeutics Market is all set to incorporate the ongoing as well as future trend.Psoriasis is an autoimmune skin disease that causes scaling, skin redness and irritation. Psoriasis causes red, scaly patches that are generally found on the elbows, fingernails, scalp, palms, knees, face, feet and inside the mouth. Factors that can trigger psoriasis include infections, heavy alcohol consumption, cold weather, certain medications, smoking, stress and injury to the skin such as bug bite, cut and sever sunburn. The signs and symptoms of psoriasis vary from person to person which includes dry, cracked skin that may bleed, red patches of skin covered with silvery scales, small scaling spots, itching, burning, swollen and stiff joints.

Psoriasis may be classified into various types such as plaque psoriasis, scalp psoriasis, pustular psoriasis, psoriatic arthritis, guttate psoriasis, nail psoriasis, erythrodermic psoriasis and inverse psoriasis. Various treatments for psoriasis are oral medication, topical medication and biologics injections. Psoriasis can also be treating by phototherapy treatment which includes ultraviolet light therapy, laser treatment, tanning beds, psoralen +UVA and sunlight treatment. Psoriasis can occur in any part of the body and it is associated with other health conditions such as heart disease, diabetes and depression.

Get Sample Copy of this Report@https://www.persistencemarketresearch.com/samples/3086

North America, followed by Europe, has the largest market for systemic psoriasis therapeutics due to emergence of novel therapies and rise in treatment seeking population in the region. Asia is expected to show high growth rate in the systemic psoriasis therapeutics market in next few years due to increase in the awareness of disease in the region.

Technological advancement, rise in number of psoriasis patients, development of novel drugs, increasing disease awareness and improvement in diagnostic methods are some of the key factors driving the growth for global systemic psoriasis therapeutics market. In addition, long-term treatment involving continuous uptake of biologics are expected to drive the market for systemic psoriasis therapeutics. However, adverse side effects associated with psoriatic drugs and economic downturns are some of the key factors restraining the growth for global systemic psoriasis therapeutics market.

Request for Table of Content@https://www.persistencemarketresearch.com/toc/3086

Growing demographics and economies in the developing countries such as India and China are expected to offer high growth in systemic psoriasis therapeutics market in Asia. In addition, growing demand of novel therapies for psoriasis treatment is expected to develop good opportunity for global systemic psoriasis therapeutics market. However, safety concern associated with systemic psoriasis therapeutics is expected to lead a challenge for systemic psoriasis therapeutics market.

Some of the major trends that have been observed for systemic psoriasis therapeutics market are increasing use of combination therapies for treating psoriasis, emergence of non-invasive psoriasis treatment and technological advancement in the field.

Some of the major companies operating in the global systemic psoriasis therapeutics market are AbbVie Inc., Stiefel Laboratories, Inc., Biogen Idec, Novartis AG, CELGENE CORPORATION, Takeda Pharmaceutical Company Limited, Pfizer Inc., Amgen Inc., Janssen Biotech, Inc. and Eli Lilly and Company.

Access Full Report@https://www.persistencemarketresearch.com/checkout/3086

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers experience by acting as the missing link between customer relationships and business outcomes. The best possible returns are assured therein.

Contact Us:

Persistence Market ResearchAddress 305 Broadway, 7th Floor, New York City, NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Salessales@persistencemarketresearch.comWebsite https://www.persistencemarketresearch.com

Continued here:
The Systemic Psoriasis Therapeutics Market To Grow On An Unparalleled Note In The Next 10 Years The Courier - The Courier

Psoriasis is a chronic inflammatory skin disorder that is accompanied with various clinical manifestations and is caused due to the involvement of genetic, environmental, and immunological factors

Global Psoriasis Market report studies the overall industry scenario breaking them down in different segments that includes geographic coverage, product type and its application. This report covers the basic market dynamics, market size and companies competition data. In addition, the report also conducts recent market developments, growth analysis by its size or volume, investment return, revenue (value), and consumption (volume) of the global Psoriasis market, ongoing pattern, the effect of covid19 on worldwide or local Psoriasis Market.

This report also covers the impact of COVID-19 on the global market. To Know How COVID-19 Pandemic Will Impact Psoriasis Market |

Get a Sample Copy of Report, Click Here: https://www.reportsweb.com/inquiry&RW00014273008/sample

Key Questions:

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Psoriasis drugs

How many Psoriasis drugs are developed by each company

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Psoriasis

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Psoriasis therapeutics

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies

What are the clinical studies going on for Psoriasis and their status

What are the key designations that have been granted to the emerging drugs

Scope of the Report:

Detailed overview of Psoriasis market Trends

Defining the opportunities and constraints witnessed by the key drivers of the industry

Includes value chain analysis, porter five forces model analysis, CAGR and cost structure analysis

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Company profiling with detailed strategies, financials growth, and recent developments

Get this report at a discounted rate @ https://www.reportsweb.com/inquiry&RW00014273008/discount

This report offers detailed TOC of Psoriasis Market:

Psoriasis Product Definition

Global Psoriasis Market Manufacturer Share and Market Overview

Manufacturer Psoriasis Business Introduction

Global Psoriasis Market Segmentation by (Region Level, Product Type Level, Industry Level, Channel Level

Psoriasis Market Forecast

Psoriasis Segmentation Product Type

Psoriasis Segmentation Industry

Psoriasis Cost of Production Analysis by (Raw Material Cost Analysis, Technology Cost Analysis, Labor Cost Analysis, Cost Overview, Conclusion

To get this report at a profitable rate @ https://www.reportsweb.com/buy&RW00014273008/buy/3000?source=shikha

Contact Info:Name: Sameer JoshiEmail:sales@reportsweb.comCompany Name: ReportsWebWebsite: Reportsweb.com

Phone: +1-646-491-9876

About ReportsWeb:

ReportsWeb.com is a one stop shop of Market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Read the rest here:
Psoriasis Market Emerging Competitive Strategies, Key Manufacturers, New Project Investment by 2025 The Manomet Current - The Manomet Current

This article is a sponsored collaboration between Bodewell and PAPER

For people living with skin conditions like eczema and psoriasis (and compromised skin), the journey to self-improvement and acceptance can be a long and arduous process. In the US alone, eight million people have been diagnosed with psoriasis, while over 30 million have eczema.

But even though these skin conditions (there is still no known cure) are relatively common, the psychological effects take a considerable toll on mental health. According to a National Eczema Association study, participants were three times at a higher risk for depression or anxiety, while 50% said their conditions interfere with their social life and intimate relationships.

When it comes to skincare brands that are focused on helping people who suffer from these skin conditions, they are underwhelming both from a product perspective, and a human empathy perspective.

Bodewell, a medicated skincare company tailored to people with eczema, psoriasis and sensitive skin, has set out to change this status quo. Its ultimate mission is to de-stigmatize skin conditions and build a supportive community around those on their healing journey, which is often inextricably linked to self-love and self-worth.

The brand's co-founder, Jamie Duff, suffered from severe eczema for 30 years and launched Bodewell as an answer to the struggles he faced. Over the years he explored holistic treatments such as vedic meditation, yoga, yogic breathing and cognitive behavior therapy that all take a more human-centered approach to the inner and outer effects of the origins of these inflammatory skin conditions. He thinks this approach can also benefit others.

More directly, Bodewell has developed (alongside CPG powerhouse P&G) treatments that they refer to as "next generation medicated skincare": plant-technology powered, scientifically-tested and proven, unique anti-inflammatory mechanism of action that hydrates, stops itching, repairs skin barrier and prevents future flare-ups. There's also a personalized digital and mobile program that supplements the products and supports customers through their journey. This program draws on co-founder Jamie's own experiences.

To capture the overlooked beauty of chronic skin sufferers, Bodewell launched an ongoing portrait series named Skincare For the Rest of Us, where it highlights real sufferers on their own terms. In this special editorial feature shot by Issey Gladston (an eczema sufferer herself) the portraits celebrate the scars as a visual tale of strength, perseverance, overcoming adversity and embracing self-love.

What's something people who have never experienced your skin condition be surprised to know or don't know about what it's like to live with it?

Human beings are preconditioned to prefer that which is aesthetically pleasing, so naturally a skin condition attracts attention because it looks different. I think a lot of people are surprised when they realize it can be quite sore/painful and can even impact common everyday tasks like sleep. My own personal experience has reminded me that skin is not an aesthetic. Skin is for function touch, temperature regulation, process pain. Our largest organ keeps all our other organs safe.

How were you able to come to terms with your condition and overcome any obstacles you've had to endure?

Self acceptance. Accepting how you have been created and navigating it to the best of your ability is the first step to overcoming. There is a silver lining in everything. My skin condition realigned me to my true creative purpose modeling and painting.

How has Bodewell helped you on your journey to self-improvement and acceptance?

I have been campaigning for brands to shoot atopic skin since 2017. It was important for me that brands particularly dry skin and atopic skin brands who include their target market in their modeling campaigns understand our lived experiences and not sell unrealistic dreams of perfect skin to those living with chronic skin conditions. Bodewell has championed skin representation and created opportunities for me as a skin model. My confidence goes up every time I shoot with Bodewell and I feel motivated to challenge other brands to shoot and include atopic skin.

What's something people who have never experienced your skin condition would be surprised to know or don't know about what it's like to live with it?

I think a lot of people would be surprised to know psoriasis is not contagious in any way. Living with my plaque psoriasis can be very sore and itchy, but it's taught me a lot of self-confidence.

How were you able to come to terms with your condition and overcome any obstacles you've had to endure?

Instagram helped me a LOT with coming to terms with my skin condition. My skin progressed slowly over many years, but with it my confidence also grew. In regards to obstacles, I've had to get used to my skin getting more sore and flaky over the last couple of years but it's something I am learning to come to terms with.

How has Bodewell helped you on your journey to self-improvement and acceptance?

Bodewell has helped me massively to embrace my skin and also to try new things, such as the photo shoot, that would normally be so outside of my comfort zone. They're an amazing company that genuinely care and really help me and the other girls to embrace our skin.

What's something people who have never experienced your skin condition would be surprised to know or don't know about what it's like to live with it?

The fact that my skin reproduces at the speed it does! I can go to sleep with a clear face and wake up a few hours later to new patches out of nowhere! You never know what you will get with psoriasis. Another classic favorite of mine is having a brush and dustpan on standby for the morning when it's time to get all my fallen skin from scratching all night off the bed and off the floor.

How were you able to come to terms with your condition and overcome any obstacles you've had to endure?

I got to a point where hiding it was no longer an option it was draining physically and mentally. I put 100% into hiding something about myself simply because I didn't want to make other people uncomfortable, but I finally got to a point where I needed my comfort to be more important than those of other people. I needed to put myself first for once.

How has Bodewell helped you on your journey to self-improvement and acceptance?

Bodewell helped me to let go of the fear of not being on medication. I felt dependent on prescription medication. If I didn't have it, that would mean a flare up and there was no way I could allow that. I only ever truly accepted the Michelle who would occasionally have clear skin from time to time but flare-up Michelle was difficult to love. Bodewell opened my eyes to different ways of healing my skin. I no longer feel dependent on medication and I'm happy with myself with or without a flare. I now understand that I'm on a journey with my condition and it's not one I need to rush.

What's something people who have never experienced your skin condition would be surprised to know or don't know about what it's like to live with it?

It is surprisingly beautiful, the way in which it inhabits certain areas of the skin, in the most fascinating accumulation of patterns is quite amazing.

How were you able to come to terms with your condition and overcome any obstacles you've had to endure?

Self-acceptance and patience. It can be quite a debilitating condition to deal with. However, learning the skill of self-acceptance and love for oneself helps to overcome those debilitating obstacles.

How has Bodewell helped you on your journey to self-improvement and acceptance?

Bodewell offered me a community where I felt safe to discuss my skin condition and tips on living with a skin condition. They gave me modeling opportunities which helped with my self-confidence and to become an active skin campaigner.

What's something people who have never experienced your skin condition be surprised to know or don't know about what it's like to live with it?

Surprisingly, my confidence in my body image, character and relationships with others has really been amplified whilst going through my journey with psoriasis. We usually hear stories relating to the negatives to having a skin condition which is just as important, however, my perspective on other aspects of my life has really changed for the better!

How were you able to come to terms with your condition and overcome any obstacles you've had to endure?

Growing up since the age of 9 with psoriasis being an extremely sporty young girl, I've almost been forced into dealing with my skin, but it wasn't until lockdown 2020 (the time of my worst flare up) that I was literally left to do nothing but look at myself daily and learn to accept, love and nurture my skin with every itch of itself.

How has Bodewell helped you on your journey to self-improvement and acceptance?

Seeing the large community that was built by so many inspiring people be celebrated by a brand like Bodewell, particularly having all-women shoots, is extremely refreshing and comforting. The creams and serums have become staples in my regime and I've definitely stepped up my skincare game to the next level. Their products are not only amazing for me, but they truly reach such a wide audience which I know will continue to grow into a wholesome and well-loved brand.

What's something people who have never experienced your skin condition would be surprised to know or don't know about what it's like to live with it?

I think the one thing I'd like people to know who have never had to deal with eczema is that it is not just a dry skin condition. It's so much more than that. It's debilitating and, depending on the severity, life altering. We have to cater our whole lives around our skin. It's not something as simple as making sure you've put moisturizer on for the day. It's the constant itching that never ends and feels like you can never do enough. It's the painful tears and cracks as our skin is so sensitive that just a touch will have it crumble. It's always worrying about skin infections due to this. It's being terrified to have a shower because the water feels like knives on our skin. It's always having to worry about the weather conditions and if we've prepped our skin well enough including having to make sure we have all our cream and medicines in our bag if we know we'll be out of the house for longer than 5 minutes. I could go on and on but I need people to know that just applying e45 isn't the solution to our problem.

How were you able to come to terms with your condition and overcome any obstacles you've had to endure?

I was always tired of not seeing the representation we as a community deserve and pushing for more inclusivity, especially as a dark skinned South Asian woman, is something that I am very passionate about and always pushing for in all sectors. So my support system, who come in the form of my best friends and the online eczema and TSW community, really gave me the confidence to put myself out there especially on social media where your appearance is held to such a high unrealistic standard and has made me realize that beauty will forever and always be more than skin deep and made me see real beauty that isn't just on the outside.

How has Bodewell helped you on your journey to self-improvement and acceptance?

I am so grateful for platforms like Bodewell, who not only provide products for people which chronic skin conditions, but also allow us to have a voice and spread awareness. Being able to not only have your say, but also listen and hear others who you can relate to has massively helped. Knowing that even though we still have a long way to go with gaining social acceptance and inclusivity, they are helping pave the way for so many of us warriors and are helping make a happy healthy change in the way we see beauty and skin conditions.

Photography: Issey Gladston

Related Articles Around the Web

See more here:
Bodewell Is the Community-Powered Brand for Chronic Skin - PAPER - Papermag

How to coach your child through any tricky social situation.

iStock

Pediatric psoriasis is difficult for kids to live with. Most notably because the red, scaly plaques that are the conditions calling card can not only be physically uncomfortable but draw unwanted attention. And when youre a kid, thats the last thing you wantwhich may be why adolescents with psoriasis tend to have increased levels of depression and anxiety, according to research published in Anais Brasileiros De Dermatologia. When attention is brought to an area, [a child] can feel embarrassed or ashamed, which can often lead to feelings of anxiety and isolation, says Johanna Kaplan, Ph.D., clinical psychologist and director of Washington Anxiety Center of Capitol Hill in Washington, D.C.

As a parent its difficult to see your child struggle. But you might not always know what to do or say to help. Start with these expert tips on how to deal with the four most common scenarios your child may encounter because of their psoriasis, so you can coach your child to handle themselves with strength and pride.

As a parent, its common to feel a wide range of emotions, from anger and sadness to guilt and grief, as well as a strong need to protect your child. Know that you may have to manage your Mama or Papa Bear tendencies.

Parents may feel like calling or going to the school to confront a teacher or an administrator, however, the child may not want so much attention drawn to them and so much discussion about their illness, says Elena Mikalsen, Ph.D., chief of pediatric psychology at The Childrens Hospital of San Antonio in San Antonio, TX. Its also important for the child to get at least some choice about how their illness is discussed and to feel mastery over being able to handle these discussions. With chronic illness, you often feel a lack of control, so any chance we can give kids control, we prefer to do that.

Therefore, Mikalsen encourages parents to discuss with their child whether mom or dad should intervene for them or if they prefer to handle the situation on their own. Though parents cant always control how people respond to their childs skin condition, they can model how to react in public and educate rather than get angry and defensive, she says.

Once youve talked with your child about ways you might (or might not) help, its time to prep your kid to take charge of any social situation that might arise. Heres how.

The very first thing a child of any age should be advised to do if teased about their psoriasis is to let an adult whom they trust know. This person can be a teacher, a family friend, a babysitter, or even the parent themselves. With an adults help, pre-planning comeback statements to use when they are teased by other children can help them feel more confident and less likely to be caught off-guard by bullies or insensitive students, according to Whitney Casares, M.D., a pediatrician in Portland, OR, and author of The Working Mom Blueprint: Winning at Parenting Without Losing Yourself .

Children might need help practicing their comebacks and knowing when it is an appropriate time to use them vs. when its best to rely on other friend groups or adults to protect them. Workshop the various types of teasingsuch as joking, name-calling, and bullying, so your child can decipher what route to take and when. By placing these actions on a continuum from mild to severe, it can help your child know what action to take.

For instance, if one of your childs peers jokes with them during P.E. class that their pants (worn to cover plaques) will slow them down, help them draft a comebackand it could be as simple as: the child sprinting to a finish line and saying afterwards, 'was that slow enough for you?' Pre-planning these exchanges could help build up your childs confidence. For more severe types of bullying, discuss the role teachers play.

To help alleviate the anxiety they have surrounding their condition, kids with psoriasis often choose to wear clothes that cover their flare-ups, even when its not in season (pants and long sleeves during summer). If another child comments on your childs psoriasis-concealing outfit, arm your child with the tools to make it a teaching moment about their skin condition, Dr. Casares says.

Give your child a script or talking points that they can use to briefly explain their medical diagnosis to their peers. By increasing others level of knowledge, theyll also increase others level of empathy, Dr. Casares says. When a childs peers have a deeper knowledge base around a specific disease like psoriasis, theyll be more likely to be supportive and less likely to tease or question the childs choices or needs.

The plaques caused by psoriasis are red and scaly, especially when theyre inflamed, which can draw unwanted attention to your childs skin as well as unwarranted comments from their peers. Support your child by role-playing situations that might arise, such as when other children ask innocent questions about their plaques, suggests Dr. Casares.

When children with psoriasis are able to differentiate when they are being teased vs. when others are genuinely curious about their disease, they can more easily navigate uncomfortable conversations, she says. Theyll also develop more confidence and acceptance of themselves as unique individuals. This is another situation that could become a teaching moment for your child and their peers. By educating your child more about their condition, such as its causes and symptoms, together you could create responses to the various comments they get about their plaques.

Unfortunately, this is a common scenarioone that you should definitely anticipate. The pool can be one of the most intimidating environments for children with psoriasis given large portions of skin are exposed, explains Dr. Casares. When children are discriminated against at a pooleither by exclusion from entering the water due to concerns from uninformed staff or via exclusion from insensitive peersit can be devastating and unjust.

Coach your child to speak with trusted adultssuch as a teacher, counselor, or parent of a friend, who can advocate on their behalf if other children discriminate against them. Advocacy is important in this situation so that the discrimination is not perpetuated and so that kids with psoriasis are less likely to be discriminated against in the future, Dr. Casares says.

And be proactive, suggests, Laurie Zelinger, Ph.D., a psychologist and parenting expert based in Cedarhurst, NY. Talk to summer camp and school administrators, pool management, or the head lifeguard before your child goes to the pool. This way they dont have to hear any discussions about their condition with the gatekeeper, she says. And if that isnt possible, pack a doctors note in their bag that states it is safe for them and others to swim together

Going through life with psoriasis and coping with the social fallout can be challenging for your family, but dont think you have to do it alone.

Connect your child with others who have the same condition so that they can discuss their experiences. You can do this by signing them up for a support group via the National Psoriasis Foundation, or even asking your childs dermatologist if they have a similar-aged patient who may be open and willing to connect with your child, says Marisa Garshick, M.D., a board-certified dermatologist at Medical Dermatology & Cosmetic Surgery (MDCS) in New York City. This can do wonders for your childs self-confidence, self-esteem, and mood.

Having a chronic condition during childhood can be significant and if you are noticing any changes in the mental health of your child, be sure to make your doctor aware so they can help identify and address the emotional impact of the disease, Dr. Garshick says.

By taking the steps to prepare your child for the social challenges that they may experience because of psoriasis, you are creating a foundation for understanding and for tolerating the discussions surrounding their condition. This is important because it builds up their confidence and reminds them that they are not defined by this condition alone.

Meet Our Writer

Jenn Sinrich is a Boston-based freelance writer, editor, and content strategist with a passion for all things health and beauty. She's also a proud new Mama to a one-month old daughter named Mila. In addition to Health Central, she contributes to publications including SELF, Readers Digest, Womens Health, Glam, Livestrong.com, Parents and more.

Go here to read the rest:
How to Coach Your Child Through Tough Situations Involving Their Psoriasis - HealthCentral.com

Mild To Moderate Plaque Psoriasis Market Insight, Epidemiology and Market Forecast 2030

The global Mild To Moderate Plaque Psoriasis is projected to grow from USD xx mllion in 2020 to USD xx million by 2027, at a CAGR of xx% from 2021 to 2030. The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the markets historic and forecast market growth by geography.

Key Questions Answered in Market Report:-

Get sample copy of thisreport @

https://www.infinitybusinessinsights.com/request_sample.php?id=473646

TOP Key Players @ Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira Inc., Novartis, Galectin Therapeutics, Cellceutix Corporation and Biogen Inc., Bayer

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Mild To Moderate Plaque Psoriasis market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global Mild To Moderate Plaque Psoriasis Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Mild To Moderate Plaque Psoriasis Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Mild To Moderate Plaque Psoriasis Market?

What are the key market trends impacting the growth of the Global Mild To Moderate Plaque Psoriasis Market?

What are the challenges to market growth?

Who are the key vendors in the Global Mild To Moderate Plaque Psoriasis Market?

What are the market opportunities and threats faced by the vendors in the Global Mild To Moderate Plaque Psoriasis Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Mild To Moderate Plaque Psoriasis Market;

3.) The North American Mild To Moderate Plaque Psoriasis Market;

4.) The European Mild To Moderate Plaque Psoriasis Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

Mild To Moderate Plaque Psoriasis Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Up to 20% Discount on this Premium Report @

https://www.infinitybusinessinsights.com/request_sample.php?id=473646

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Infinity Business Insightsis a market research company that offers market and business research intelligence all around the world. We are specialized in offering the services in various industry verticals to recognize their highest-value chance, address their most analytical challenges, and alter their work.

We attain particular and niche demand of the industry while stabilize the quantum of standard with specified time and trace crucial movement at both the domestic and universal levels. The particular products and services provided by Infinity Business Insights cover vital technological, scientific and economic developments in industrial, pharmaceutical and high technology companies.

Contact Us:

Amit J

Sales Coordinator

+1-518-300-3575

amit@infinitybusinessinsights.com

https://mobile.twitter.com/IBInsightsLLP

https://facebook.com/Infinity-Business-Insights-352172809160429

https://www.linkedin.com/company/infinity-business-insights/

Read more:
Globel Mild To Moderate Plaque Psoriasis Market Scope and Forecast By 2021-2030 Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira...

Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA)- Market Insight, Epidemiology and Market Forecast -2030

The global market for Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) estimated at USD XX million in the year 2020, is projected to reach a revised size of USD XX million by 2027, growing at a CAGR of XX % over the analysis period 2020-2027. The report provides the analysis of the Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) market across different regions.

It aims at estimating the market size and future growth potential of this market across different segments such as form, end-use industry, and type. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, SWOT analysis, recent developments, and key market strategies.

Get sample copy of thisreport @

https://www.infinitybusinessinsights.com/request_sample.php?id=473652

TOP Key Players @ Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira Inc., Novartis, Galectin Therapeutics, Cellceutix Corporation and Biogen Inc., Bayer.

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market?

What are the key market trends impacting the growth of the Global Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market?

What are the challenges to market growth?

Who are the key vendors in the Global Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market?

What are the market opportunities and threats faced by the vendors in the Global Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market;

3.) The North American Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market;

4.) The European Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Up to 20% Discount on this Premium Report @

https://www.infinitybusinessinsights.com/request_sample.php?id=473652

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Infinity Business Insightsis a market research company that offers market and business research intelligence all around the world. We are specialized in offering the services in various industry verticals to recognize their highest-value chance, address their most analytical challenges, and alter their work.

We attain particular and niche demand of the industry while stabilize the quantum of standard with specified time and trace crucial movement at both the domestic and universal levels. The particular products and services provided by Infinity Business Insights cover vital technological, scientific and economic developments in industrial, pharmaceutical and high technology companies.

Contact Us:

Amit J

Sales Coordinator

+1-518-300-3575

amit@infinitybusinessinsights.com

https://mobile.twitter.com/IBInsightsLLP

https://facebook.com/Infinity-Business-Insights-352172809160429

https://www.linkedin.com/company/infinity-business-insights/

Here is the original post:
Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market Scope and Forecast By 2021 to 2028-Allergan, Johnson and Johnson, Amgen, Abbvie, Eli...

Moderate Psoriasis- Market Insight, Epidemiology and Market Forecast -2030

The global market for Moderate Psoriasis estimated at USD XX million in the year 2020, is projected to reach a revised size of USD XX million by 2027, growing at a CAGR of XX % over the analysis period 2020-2027. The report provides the analysis of the Moderate Psoriasis market across different regions.

It aims at estimating the market size and future growth potential of this market across different segments such as form, end-use industry, and type. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, SWOT analysis, recent developments, and key market strategies.

Get sample copy of thisreport @

https://www.infinitybusinessinsights.com/request_sample.php?id=473649

TOP Key Players @ Merck & Co., Abb Vie Inc., Amgen Inc., Eli Lilly & company, Sun Pharmaceutical Industries Ltd, Novartis International AG, Janssen Biotech Inc., Pfizer Inc., and Boehringer Ingelheim GmbH, among others.

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Moderate Psoriasis market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global Moderate Psoriasis Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Moderate Psoriasis Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Moderate Psoriasis Market?

What are the key market trends impacting the growth of the Global Moderate Psoriasis Market?

What are the challenges to market growth?

Who are the key vendors in the Global Moderate Psoriasis Market?

What are the market opportunities and threats faced by the vendors in the Global Moderate Psoriasis Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Moderate Psoriasis Market;

3.) The North American Moderate Psoriasis Market;

4.) The European Moderate Psoriasis Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

Moderate Psoriasis Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Up to 20% Discount on this Premium Report @

https://www.infinitybusinessinsights.com/request_sample.php?id=473649

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Infinity Business Insightsis a market research company that offers market and business research intelligence all around the world. We are specialized in offering the services in various industry verticals to recognize their highest-value chance, address their most analytical challenges, and alter their work.

We attain particular and niche demand of the industry while stabilize the quantum of standard with specified time and trace crucial movement at both the domestic and universal levels. The particular products and services provided by Infinity Business Insights cover vital technological, scientific and economic developments in industrial, pharmaceutical and high technology companies.

Contact Us:

Amit J

Sales Coordinator

+1-518-300-3575

amit@infinitybusinessinsights.com

https://mobile.twitter.com/IBInsightsLLP

https://facebook.com/Infinity-Business-Insights-352172809160429

https://www.linkedin.com/company/infinity-business-insights/

The rest is here:
Moderate Psoriasis Market Scope and Forecast By 2021 to 2028-Merck & Co., Abb Vie Inc., Amgen Inc., Eli Lilly & company, Sun Pharmaceutical...

INDIANAPOLIS, June 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present new data from Phase 3 studies that further demonstrated the long-term efficacy and safety profile of Taltz(ixekizumab) among patients with axial spondyloarthritis (axSpA). These results are being presented at the virtual Annual European Congress of Rheumatology (EULAR), June 2-5, 2021.

AxSpA is recognized as a single disease entity, with two subtypes which are defined depending on the presence (radiographic axSpA, or r-axSpA) or absence (non-radiographic axSpA, or nr-axSpA) of defined structural damage of the sacroiliac joints on plain x-ray films as per the modified New York (mNY) criteria.

"Patients living with axial spondyloarthritis deal with a range of chronic, debilitating symptoms, including inflammatory back pain, and are in need of treatment options that can provide long-term efficacy," said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. "We are excited to present a range of new data at EULAR that demonstrate treatment with Taltz provides consistent, long-term efficacy on common signs and symptoms over time in axial spondyloarthritis."

Taltz Showed Sustained Long-Term Improvements in axSpA Through Two Years

In COAST-Y, Taltz showed consistent and sustained long-term improvements in signs and symptoms, functionality and quality of life in patients with r- and nr-axSpA. In this study, more than half of patients (56.7%) treated continuously with Taltz (80 mg every four weeks, n=157) through two years achieved Assessment of SpondyloArthritis international Society 40% response (ASAS40).

Among those treated continuously with Taltz every four weeks for two years:

The safety profile of Taltz was consistent with previously published safety data, and no new safety signals were observed after up to two years of treatment.

For methodology, see the "About the Analyses" section below. Additional results from the Phase 3 COAST-Y study were also recently published in the Annals of the Rheumatic Diseases.

Most Patients Treated with Taltz Did Not Show Bone Damage Progression of r-axSpA Up to Two Years

An analysis of two Phase 3 studies in r-axSpA (COAST-V and COAST-W) and the long-term extension trial (COAST-Y), found that 9 out of 10 patients treated with Taltz (89.6%, n=206) did not show radiographic progression for up to two years, as measured by mean change from baseline of modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) <2. Overall mean rates of progression were low among patients treated with Taltz. These results were similar among patients who were previously treated with anti-TNF therapy (88%, n= 106) and those who had not previously been treated with a biologic (91%, n=100). For methodology, see the "About the Analyses" section below.

"If left uncontrolled, individuals living with active radiographic axSpA can experience severe, chronic pain and structural damage in the spine that can lead to fusion of the spine and loss of mobility," said Walter P. Maksymowych, M.D., FRCP (C), Professor of Medicine at the University of Alberta, and Chief Medical Officer, CARE Arthritis, Edmonton, CA, and the senior author of this analysis. "Most patients treated with ixekizumab did not show structural damage progression at two years, and the degree of progression was small. In addition to known predictors, the novel finding is that attainment of remission of inflammation on MRI at one year protected from progression at two years."

Notably, Lilly will also present new analyses in axSpA and psoriatic arthritis, including the following:

More than 175,000 patients have been treated with Taltz worldwide since launch, giving healthcare providers confidence in making informed prescribing decisions for the treatment of adults with active psoriatic arthritis, active ankylosing spondylitis, active nr-axSpA and moderate to severe plaque psoriasis.

About the Analyses

INDICATIONS AND USAGE FOR TALTZ Taltz is approved for the treatment of patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy and for the treatment of adults with active psoriatic arthritis, active ankylosing spondylitis, or active non-radiographic axial spondyloarthritis with objective signs of inflammation.

IMPORTANT SAFETY INFORMATION FOR TALTZ

CONTRAINDICATIONSTaltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS InfectionsTaltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Hypersensitivity Serious hypersensitivity reactions, including angioedema and urticaria (each 0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel Disease Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.

Immunizations Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

ADVERSE REACTIONS Most common adverse reactions (1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, oropharingeal pain and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis and conjunctivitis, influenza, and urticaria in pediatric psoriasis (also common). Adverse drug reactions in patients with radiographic axial spondyloarthritis (ankylosing spondylitis) were similar with the exception of inflammatory bowel disease (common) and rhinitis (common). In patients with non-radiographic axial spondyloarthritis, adverse events were also similar to inflammatory bowel disease (common), influenza (common) and conjunctivitis (common).

Please see full Prescribing Information and Medication Guide for Taltz. See Instructions for Use included with the device.

IX HCP ISI 07MAY2020

About TaltzTaltz is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses.Taltz inhibits the release of pro-inflammatory cytokines and chemokines.

About Axial SpondlyoarthritisAxial spondyloarthritis (axSpA), which includes both radiographic axSpA (r-axSpA) and non-radiographic axSpA (nr-axSpA), is a disease predominantly affecting the sacroiliac joints and the spine. Common symptoms include chronic inflammatory back pain, fatigue and stiffness.1,2,3It is estimated that 2.3 million people in the U.S. have axSpA, and approximately half of those individuals live with nr-axSpA.2,4For patients with r-axSpA, the disease is characterized by the presence of structural damage of the sacroiliac joints that appears on an X-ray, while patients with nr-axSpA do not have clearly detectable structural damage radiographically.5These two patient subsets share a similar burden of disease and similar clinical features, but approved biologic treatment options for patients with nr-axSpA are much more limited and patients are often underdiagnosed.5,6

About Lilly in ImmunologyLilly is bringing our heritage of championing groundbreaking, novel science to immunology and is driven to change what's possible for people living with autoimmune diseases. There are still significant unmet needs, as well as personal and societal costs, for people living with a variety of autoimmune diseases and our goal is to minimize the burden of disease. Lilly is investing in leading-edge clinical approaches across its immunology portfolio in hopes of transforming the autoimmune disease treatment experience. We've built a deep pipeline and are focused on advancing cutting edge science to find new treatments that offer meaningful improvements to support the people and the communities we serve.

About Eli Lilly and CompanyLilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/news. P-LLY

Lilly Forward-Looking StatementThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Taltz (ixekizumab) as a treatment for ankylosing spondylitis, radiographic and non-radiographic axial spondylorarthritis, and psoriatric arthritis, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that Taltz will receive additional regulatory approvals or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

1 Reveille JD, et al. Prevalence of axial spondylarthritis in the United States: Estimates from a cross-sectional survey. Arthritis Care Res. 2012;64(6):905-910.

2 Strand V, et al. Prevalence of axial spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis. Arthritis Care Res. 2013;65(8):1299-306.

3 Kiltz U, et al. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res. 2012;64(9):1415-22.

4 U.S. Census Bureau, Population Estimates Program (PEP) https://www.census.gov/quickfacts/fact/table/US# accessed on April 30, 2020.

5 Deodhar A, et al. The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis International Society in response to the US Food and Drug Administration's comments and concerns. Arth Rheum. 2014;66(10):2649-2656.

6 De Miguel Mendieta E, et al. Ann Rhuem Dis. 2018;77:1156. Abstract AB0857.

# # #

SOURCE Eli Lilly and Company

https://www.lilly.com/

Read more:
Taltz Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study - PRNewswire

() Stuart Ashman joins Proactive London to discuss results from a study of people suffering from psoriasis that received its immune system-modulating food supplement delivering results that exceeded expectations.

In all 91 people with the condition completed the 56-day self-managed consumer study with 76% of the group reporting their skin felt less itchy, and 75% saying it appeared less red.

Ashman says the findings from the assessment of AxisBiotix-Ps, developed in collaboration with partner Winclove Probiotics, will pave the way for a commercial launch of the product in the fourth quarter.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

See the original post:
SkinBioTherapeutics "delighted" with psoriasis study results, with 76% reporting less itchy skin - Proactive Investors UK